It truly is a sad state of affairs if/when smaller biotechs fail to deliver cures because of the greed of some on Wall Street, and let's not forget the unscrupulous hedge funds located off-shore that get away with this, too! And, let's not forget what the Big 3 Automakers have done to "upstarts" in that industry, either ... why not look under the Big Pharma rock while we're at it!
Well, something had to have sparked the interest today. If it was strictly anticipation, we would have deflated by now. There's accumulation going on, it appears. Read the background info on today's conference ... it attracts Wall St. $$$$.
Looks to me on the conference web page that some companies are webcasting and some are not. Don't know why ... but there are quite a few others that chose not to, apparently.
“Show me a young Conservative and I'll show you someone with no heart. Show me an old Liberal and I'll show you someone with no brains.” - Winston Churchill
Well if it was speculative buying, the air will come out once Robin finishes, unless she says something very positive. We probably saw a little nervous short covering today, too. Tick tock!!
Seems odd, though ... unless there was a leak of some kind. There was no positive movement going into any of the other conferences this month?
I bet you are a window peeper by night, also JSY!! You mock others, while you do the same. Hypocritical much?
I can't stay in the barn today ... I'm busy making $$ on my recent NBS accumulation!
How much are YOU making today sitting on this board trying to convince people to sell?
And, where's the crime in trying to clarify something? If I was "blind", I wouldn't bother, right? I would simply believe and follow?
Well, my curiosity led me to look at the entire board today ... BIG mistake! My world was much nicer without YOU in it!
And "why" does asking this question warrant THREE quick thumbs down? You're not fooling anyone, you bashing clowns!!
Find the son's blog and do the timeline. His surgery was done well in advance of his stem treatment and his baseline vision acuity was documented. The improvement after the stem treatment did NOT result from the cataract surgery. Period!!
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Agios Pharmaceuticals, Inc. (AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that clinical data from a Phase 1 study of AG-120, an orally available, selective, potent inhibitor of the mutated IDH1 protein, will be highlighted in a late breaking oral presentation at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place November 18 - 21, 2014, in Barcelona, Spain.
“We look forward to sharing the first clinical data from our AG-120 Phase 1 trial in patients with advanced hematologic malignancies during the late-breaker session at EORTC-NCI-AACR,” said David Schenkein, M.D., chief executive officer at Agios. “We believe IDH1 is an important target that has the potential to make a difference for patients with a broad range of hematologic and solid tumor cancers.”
Title: Clinical safety and activity in a phase I trial of AG-120, a first in class, selective, potent inhibitor of the IDH1-mutant protein, in patients with IDH1 mutant positive advanced hematologic malignancies.
Presentation time: Wednesday, November 19, 2014, at 2:50 p.m. CET
Session title: Plenary Session 2: Proffered Paper Session
Abstract Code: 1LBA
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals is focused on discovering and developing novel medicines to treat cancer and rare geneti
Thanks for all the info along the way.
Been quietly accumulating after being out for awhile. Story never changed ... just a little longer term than first anticipated!
That's his PERFECT platform ... speaking to the globe ... no one challenging him, reading from the teleprompter with all of his ivory tower euphemisms. He is not a realist nor pragmatic and is often behind the curve. He's essentially a Manchurian Candidate in way over his head!
Or, when I first invested in NFLX at $17 or VRTX at $7 ... one had revenue but not even close to profit and the other had neither! Not a perfect measurement of future potential!
Why don't you take some of your objections and arguments over to that board and enter a real dialogue about the pros and cons instead of taking up permanent residence here on the "short bus"? Seems like a fair question?
Sounds like the next segment on CNBC aligns with your thinking?